Global Prostate Cancer Treatment Market Research Report: Forecast (2022-27)

By Diagnosis (Tissue Biopsy, Transrectal Ultrasound, Prostate-specific Antigen Testing, Urine Testing, Imaging), By Treatment (Surgery (Radical Prostatectomy, Cryotherapy, Orchiect......omy (Surgical Castration)), Hormone Therapy (LHRH (Luteinizing Hormone-Releasing Hormone) Agonists (Leuprolide (Lupron, Eligard), Goserelin (Zoladex), Triptorelin (Trelstar), Leuprolide mesylate (Camcevi)), LHRH (Luteinizing Hormone-Releasing Hormone) Antagonists)(Degarelix (Firmagon), Relugolix (Orgovyx)), Radiation Therapy (External Beam Radiation Therapy (EBRT) (Proton Beam Radiation Therapy, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Stereotactic Body Radiation Therapy (SBRT)), Brachytherapy (Internal Radiation Therapy), Radiopharmaceuticals), Chemotherapy (Docetaxel (Taxotere), Cabazitaxel (Jevtana), Mitoxantrone (Novantrone), Estramustine (Emcyt)), Targeted Therapy (Rucaparib (Rubraca), Olaparib (Lynparza)), By End-User (Hospitals, Clinics), By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific), By Company(Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others) Read more

  • Healthcare
  • Jun 2022
  • 185
  • PDF, Excel, PPT

Market Definition

The prostate is a part of the male reproductive system, located below the bladder & in front of the rectum, surrounding the urethra. The prostate gland produces fluid, making a part of semen. When cells in the prostate multiply uncontrollably, it is said to be prostate cancer, whose early stages are usually asymptomatic, and the later stages, however, can display a few signs like:

  • Blood in the urine or semen
  • Bone pain
  • Erectile dysfunction
  • Reduced stream flow of urine
  • Trouble in urination
  • Weight loss without trying

As common as prostate cancer is becoming, the demand for its effective diagnosis & treatment is rapidly rising & instigating various companies to produce novel drugs concentrating on unmet patient needs. Ongoing developments of novel therapeutics for prostate cancer are expected to offer improved survival time, less toxicity, better progression-free survival, effectiveness, & greater affordability for the patient.

Market Insights

The Global Prostate Cancer Market is projected to grow at a CAGR of around 10.8% during the forecast period, i.e., 2022-27. Prostate cancer is one of the most common cancers in males worldwide. With its rising incidence, the demand for effective diagnosis & treatments is also surging rapidly and instigating the governments of different countries to increase their healthcare expenditures.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR (2022-2027) 10.8%
Regions Covered North America: The US, Canada, Mexico
Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
South America: Brazil, Rest of Latin America
Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled

Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others
Unit Denominations USD Million/Billion

 

It, in turn, is demonstrating increasing R&D activities associated with bringing innovations in drugs for prostate cancer therapies and encouraging the leading players to actively participate in the development, production, & distribution of more and more diagnostic equipment & therapeutic medications for patients.

Governments of several countries are spreading awareness about the availability of diagnosis & treatment for prostate cancer through advertisements, campaigns, screening tests, and by conducting & implementing programs for screening tests like Prostate-Specific Antigen (PSA) blood tests & Digital Rectal Exam (DRE) for male patients above 50 years, and other mediums.

It, in turn, is driving the patient pool for prostate cancer worldwide. Favorable policies for clinical trials of medications are instigating the leading biopharma companies to introduce affordable therapeutics. Moreover, the incorporation of technologies like Multiparametric Magnetic Resonance Imaging (mp-MRI) to enhance the identification of tumors & guide if there is a need for tissue biopsy in prostate cancer is also demonstrating increasing diagnosis and augmenting the market expansion. In addition, the approaching patent expiration of various prostate cancer drugs like Zytiga would further generate lucrative opportunities for the leading players in the Global Prostate Cancer Market over the forecast years.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Prostate Cancer Market Trends & Insights
  4. Global Prostate Cancer Market Regulation & Policy, By Country
  5. Global Prostate Cancer Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Prostate Cancer Market Hotspot and Opportunities
  7. Global Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Tissue Biopsy
        2. Transrectal Ultrasound
        3. Prostate-specific Antigen Testing
        4. Urine Testing
        5. Imaging
      2. By Treatment
        1. Surgery
          1. Radical Prostatectomy
          2. Cryotherapy
          3. Orchiectomy (Surgical Castration)
        2. Hormone Therapy
          1. LHRH (Luteinizing Hormone-Releasing Hormone) Agonists
            1.  Leuprolide (Lupron, Eligard)
            2. Goserelin (Zoladex)
            3. Triptorelin (Trelstar)
            4. Leuprolide mesylate (Camcevi)
          2. LHRH (Luteinizing Hormone-Releasing Hormone) Antagonists
            1. Degarelix (Firmagon)
            2. Relugolix (Orgovyx)
        3. Radiation Therapy
          1. External Beam Radiation Therapy (EBRT)
            1. Proton Beam Radiation Therapy
            2. Three-Dimensional Conformal Radiation Therapy (3D-CRT)
            3. Stereotactic Body Radiation Therapy (SBRT)
          2. Brachytherapy (Internal Radiation Therapy)
          3. Radiopharmaceuticals
        4. Chemotherapy
          1. Docetaxel (Taxotere)
          2. Cabazitaxel (Jevtana)
          3. Mitoxantrone (Novantrone)
          4. Estramustine (Emcyt)
        5. Targeted Therapy
          1. Rucaparib (Rubraca)
          2. Olaparib (Lynparza)
      3. By End-User
        1. Hospitals
        2. Clinics
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia-Pacific
  13. Global Prostate Cancer Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. Abbott Laboratories
      2. AbbVie Inc.
      3. Amgen Inc.
      4. AstraZeneca PLC
      5. Bayer AG
      6. Bristol Myers Squibb
      7. Eisai Co. Ltd.
      8. Eli Lilly and Company
      9. F. Hoffmann-La Roche AG
      10. GlaxoSmithKline PLC
      11. Merck & Co., Inc.
      12. Novartis International AG
      13. Pfizer Inc.
      14. Sanofi S.A.
      15. Others
  15. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now
Related Reports
Talk to our Consultant Talk to our Consultant
Customization Offered
  • Cross-segment Market Size & Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics & Share
  • Import Export & Production Analysis
Request Customization Request Customization